ULRICH BROECKEL, MD - Co-FOUNDER & CHIEF EXECUTIVE OFFICER
Ulrich Broeckel, MD, has over 20 years of experience in genetics and genomics and more than 10 years of experience in clinical diagnostics. He is an expert in translational pharmacogenomic research, and is a member of CPIC and the NIH initiatives on clinical pharmacogenomics. Dr. Broeckel serves as Professor of Pediatrics, Section Chief of Genomic Pediatrics, and Director of the Individualized Medicine Institute at the Medical College of Wisconsin.
carter cliff - co-founder & chief Business officer
Carter Cliff founded the Madison, WI, based accelerator, D1ASP0RA, and is additionally co-founder of Opsis Therapeutics. He previously served as Director of Business Development at Cellular Dynamics International (CDI), a FUJIFILM company. Prior to CDI, Mr. Cliff held positions at several leading drug discovery tools companies, including Meso-Scale Discovery, Life Technologies, Ingenuity Systems, and Upstate Biotechnology.
Gunter Scharer, MD - Chief Medical Officer
Gunter Scharer is a board-certified pediatrician and geneticist. He has over ten years of experience in clinical diagnostics. Dr. Scharer is a board-certified physician with a current practice at Children's Minnesota. Previously, he was a faculty member at the Medical College of Wisconsin.
Rachel Lorier - Director, Laboratory Operations
Rachel Lorier has over ten years of experience developing the infrastructure and managing the operation of two clinical laboratories involved in cytogenetic and pharmacogenetic testing. At RPRDx Rachel manages laboratory operations and oversees client relations. Ms. Lorier brings her many years of experience in research and clinical testing to provide clients with exceptional service.
Andrea Matter - Director, Regulatory Affairs
Andrea Matter has over ten years of experience in clinical diagnostics, as well as FDA compliance. She has written extensive GMP documentation for NADA submission, as well as developed the regulatory infrastructure for two clinical laboratories under CAP/CLIA regulation. In her role at RPRDx, Ms. Matter provides research and writes documentation to ensure clinical standards and safety regulations are consistently met.
Amy Turner - Director, Test Development
Amy Turner has over ten years of experience in complex molecular test development, and over five years of experience supervising a clinical laboratory. She has developed a wide range of experimental methodologies, from detection of complex genetic variation, to exosomal biomarker screening. During Ms. Turner’s years in clinical research she has developed and validated multiple pharmacogenetic tests and will serve as the laboratory supervisor for pharmacogenetic test development and implementation.